Market Cap 2.64B
Revenue (ttm) 0.00
Net Income (ttm) -422.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,400,500
Avg Vol 1,651,620
Day's Range N/A - N/A
Shares Out 146.66M
Stochastic %K 23%
Beta 1.11
Analysts Strong Sell
Price Target $32.21

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Synd...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 866 8547
Address:
161 Oyster Point Boulevard, South San Francisco, United States
BillionerOfKing
BillionerOfKing Dec. 11 at 6:20 PM
$DNLI Current Stock Price: $17.44 Contracts to trade: $20 DNLI Dec 19 2025 Call Entry: $1.89 Exit: $3.31 ROI: 75% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Otus
Otus Dec. 11 at 4:59 PM
$DNLI no need for shares from the secondary. It’s now trading just below a he 17.5 price. There could always be a repricing depending on demand. I haven’t yet seen the red herring.
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 2:31 PM
Wedbush updates rating for Denali Therapeutics ( $DNLI ) to Outperform, target set at 31 → 30.
0 · Reply
Drashkawisha
Drashkawisha Dec. 11 at 8:00 AM
$DNLI should stabilize at this level- watch this level if not breaks.
0 · Reply
DoctrBenway
DoctrBenway Dec. 10 at 9:01 PM
$DNLI Added 30% to a large position @ 17.53.
0 · Reply
DoctrBenway
DoctrBenway Dec. 10 at 8:09 PM
$DNLI Having been in companies that ran out of money, I say raise when you CAN not when you MUST.
0 · Reply
notreload_ai
notreload_ai Dec. 10 at 4:33 PM
$DNLI is selling about 9.1M shares at $17.50 and 2.3M pre-funded warrants at $17.49, raising roughly $200M before fees. Underwriters can buy 1.7M more shares. All securities come from Denali, and the deal is expected to close around December 11, 2025.
0 · Reply
BioTechHealthX
BioTechHealthX Dec. 10 at 4:17 PM
$DNLI Denali Therapeutics priced 9.14M shares at $17.50 and issued 2.29M pre-funded warrants at $17.49, triggering an 8.3% premarket drop. With total gross proceeds of $200M and a 30-day option for 1.71M more shares, dilution fears are rising fast. Here’s why investors are worried. https://biotechhealthx.com/biotech-news/denali-therapeutics-dnli-crashes-8-3-premarket-after-pricing-200m-offering/
0 · Reply
PnLTagX2_1488
PnLTagX2_1488 Dec. 10 at 3:51 PM
$DNLI neuro biotech, tends to build long bases then reprice sharply on catalysts
0 · Reply
Otus
Otus Dec. 10 at 2:57 PM
$DNLI I’m going to try for a piece of the add on. I’m sure I won’t get enough but who knows. I prefer the dilution now so hopefully this is all they will need before approvals. Refreshing to see some proactive planning as opposed the most companies reactive planning.
0 · Reply
Latest News on DNLI
Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More

Dec 10, 2025, 4:38 PM EST - 3 days ago

Biggest Stock Movers Today, Dec. 10: PLAB, AVAV, & More

AVAV GEV PLAB


Denali: Regulatory Delay Is A Strategic Opportunity

Dec 2, 2025, 8:09 AM EST - 11 days ago

Denali: Regulatory Delay Is A Strategic Opportunity


The Best Small-Cap Stocks to Buy Now

Aug 12, 2025, 9:47 AM EDT - 4 months ago

The Best Small-Cap Stocks to Buy Now

KYMR WAY


Denali Therapeutics: Vast Pipeline, First Approval Up Ahead

Mar 20, 2025, 2:16 PM EDT - 9 months ago

Denali Therapeutics: Vast Pipeline, First Approval Up Ahead


Why Is Denali Therapeutics Stock Trading Higher On Wednesday?

Jan 15, 2025, 2:26 PM EST - 11 months ago

Why Is Denali Therapeutics Stock Trading Higher On Wednesday?


Denali Therapeutics ALS drug fails in mid-stage trial

Jan 6, 2025, 4:43 PM EST - 1 year ago

Denali Therapeutics ALS drug fails in mid-stage trial


Denali Has A Neurodegenerative Edge Despite Market Skepticism

Nov 16, 2024, 8:56 AM EST - 1 year ago

Denali Has A Neurodegenerative Edge Despite Market Skepticism


Denali's New Summit: Changing Hunter Syndrome Landscape

Oct 2, 2023, 5:26 AM EDT - 2 years ago

Denali's New Summit: Changing Hunter Syndrome Landscape


MPS II And Beyond: Implications Of Denali's Promising Pipeline

Jul 23, 2023, 12:51 AM EDT - 2 years ago

MPS II And Beyond: Implications Of Denali's Promising Pipeline


BillionerOfKing
BillionerOfKing Dec. 11 at 6:20 PM
$DNLI Current Stock Price: $17.44 Contracts to trade: $20 DNLI Dec 19 2025 Call Entry: $1.89 Exit: $3.31 ROI: 75% Hold ~21 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
Otus
Otus Dec. 11 at 4:59 PM
$DNLI no need for shares from the secondary. It’s now trading just below a he 17.5 price. There could always be a repricing depending on demand. I haven’t yet seen the red herring.
0 · Reply
JarvisFlow
JarvisFlow Dec. 11 at 2:31 PM
Wedbush updates rating for Denali Therapeutics ( $DNLI ) to Outperform, target set at 31 → 30.
0 · Reply
Drashkawisha
Drashkawisha Dec. 11 at 8:00 AM
$DNLI should stabilize at this level- watch this level if not breaks.
0 · Reply
DoctrBenway
DoctrBenway Dec. 10 at 9:01 PM
$DNLI Added 30% to a large position @ 17.53.
0 · Reply
DoctrBenway
DoctrBenway Dec. 10 at 8:09 PM
$DNLI Having been in companies that ran out of money, I say raise when you CAN not when you MUST.
0 · Reply
notreload_ai
notreload_ai Dec. 10 at 4:33 PM
$DNLI is selling about 9.1M shares at $17.50 and 2.3M pre-funded warrants at $17.49, raising roughly $200M before fees. Underwriters can buy 1.7M more shares. All securities come from Denali, and the deal is expected to close around December 11, 2025.
0 · Reply
BioTechHealthX
BioTechHealthX Dec. 10 at 4:17 PM
$DNLI Denali Therapeutics priced 9.14M shares at $17.50 and issued 2.29M pre-funded warrants at $17.49, triggering an 8.3% premarket drop. With total gross proceeds of $200M and a 30-day option for 1.71M more shares, dilution fears are rising fast. Here’s why investors are worried. https://biotechhealthx.com/biotech-news/denali-therapeutics-dnli-crashes-8-3-premarket-after-pricing-200m-offering/
0 · Reply
PnLTagX2_1488
PnLTagX2_1488 Dec. 10 at 3:51 PM
$DNLI neuro biotech, tends to build long bases then reprice sharply on catalysts
0 · Reply
Otus
Otus Dec. 10 at 2:57 PM
$DNLI I’m going to try for a piece of the add on. I’m sure I won’t get enough but who knows. I prefer the dilution now so hopefully this is all they will need before approvals. Refreshing to see some proactive planning as opposed the most companies reactive planning.
0 · Reply
OpenOutcrier
OpenOutcrier Dec. 10 at 1:57 PM
$DNLI (-9.5% pre) Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50 https://ooc.bz/l/87003
0 · Reply
dudleyvirgil
dudleyvirgil Dec. 10 at 11:47 AM
$DNLI Denali Therapeutics Announces Pricing of Public Offering of Common Stock at $17.50 per Share and Pre-Funded Warrants at $17.49 each Denali Therapeutics announced the pricing of its underwritten public offering of 9,142,857 shares of its common stock at a price to the public of $17.50 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 2,285,714 shares of common stock at a price of $17.49 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.01 per share exercise price for each pre-funded warrant
0 · Reply
merlin8121
merlin8121 Dec. 10 at 11:10 AM
$DNLI https://www.merlintrader.com/dnli/
0 · Reply
Drashkawisha
Drashkawisha Dec. 10 at 8:26 AM
$DNLI The "Mechanics of the Deal" explained. For those asking if the drop to ~$17.50 is a buy, here is what’s happening under the hood of this $200M offering: The "Anchor" Price ($17.50): Institutions agreed to pour $200M at this specific price. For them, this is fair value. Buying here puts you at the same entry point as the Whales. The "Pre-Funded" Signal: They aren't just selling stock; they are selling Pre-Funded Warrants. Why? Because big funds (Smart Money) are hitting their regulatory ownership caps (9.99%) and literally asked for a vehicle to buy MORE than allowed. Translation: Demand is massive. The "Green Shoe" Defense: Underwriters have a 30-day option for more shares. If the price dips below $17.50, they are incentivized to step in and stabilize. The Setup: Buy Zone: $17.50 - $17.80 (Co-investing with the funds). The Risk: A high-volume break below $17.00 = Broken deal. The Reward: Positioning for the April PDUFA run-up with a cleaned-up balance sheet.
0 · Reply
Drashkawisha
Drashkawisha Dec. 10 at 6:11 AM
$DNLI The Dilution: Clearing the Deck for Launch. 🧹🚀 Bears see "dilution"; Pros see "Confidence". Here is the breakdown of the Prelim Prospectus filed overnight: The "Why": With ~$926M in Net Tangible Book Value, they didn't need cash to survive. They raised capital specifically for "Commercial Launch activities" and "Manufacturing". You don't build a sales force unless you are sure approval is coming. The Timeline (Locked): PDUFA Date: April 5, 2026 (confirmed). The Strategy: By raising NOW (4 months prior), they remove the post-approval dilution overhang. The path to April is now clear of financial risks. The Play: This dip is a liquidity event for long-term entry. The company is transitioning from R&D to Commercial. Waiting for pricing stabilization to reload.
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Dec. 9 at 9:18 PM
0 · Reply
Tadstonk
Tadstonk Dec. 9 at 9:13 PM
$DNLI promoted their stock last week and now diluting us…again. So the 275 million from Royalty Pharma? Wtf is going on?
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 7:41 PM
Big cash infusion on the table — and $DNLI just locked it in. DNLI secured a $275M funding deal with Royalty Pharma that’s tied directly to potential approvals for its Hunter syndrome therapy, giving the program fresh momentum. Full breakdown here 👉 https://www.zacks.com/stock/news/2800334/denali-enters-into-a-275m-funding-deal-with-royalty-pharma?cid=sm-stocktwits-2-2800334-teaser-23728&ADID=SYND_STOCKTWITS_TWEET_2_2800334_TEASER_23728
0 · Reply
ZacksResearch
ZacksResearch Dec. 5 at 6:41 PM
$DNLI surges 5.84% on $275M funding deal with $RPRX! 🚀 💰 Deal centers on tividenofusp alfa, targeting Hunter syndrome 📅 FDA's target action date for tividenofusp alfa's BLA is set for April 5, 2026 Discover the full potential of this agreement 👉 https://www.zacks.com/stock/news/2800334/denali-enters-into-a-275m-funding-deal-with-royalty-pharma?cid=sm-stocktwits-2-2800334-body-23715&ADID=SYND_STOCKTWITS_TWEET_2_2800334_BODY_23715
0 · Reply
JarvisFlow
JarvisFlow Dec. 5 at 1:40 PM
Wedbush updates rating for Denali Therapeutics ( $DNLI ) to Outperform, target set at 30 → 31.
0 · Reply
JarvisFlow
JarvisFlow Dec. 5 at 10:37 AM
BTIG has adjusted their stance on Denali Therapeutics ( $DNLI ), setting the rating to Buy with a target price of 32.
0 · Reply
topstockalerts
topstockalerts Dec. 4 at 8:24 PM
Denali Therapeutics shares rose after announcing a $275 million synthetic royalty financing deal with Royalty Pharma for its Hunter syndrome drug candidate, tividenofusp alfa. The agreement includes a $200 million upfront payment and $75 million tied to European approval by the end of 2029. Royalty Pharma will receive 9.25% royalties on global sales until reaching a return multiple, contingent on accelerated FDA approval. The FDA is reviewing the therapy with a target decision date of April 5, 2026. Denali’s CEO said the deal validates the drug’s potential and supports further development using its TransportVehicle technology to treat cognitive and physical symptoms of Hunter syndrome. $DNLI $RPRX
0 · Reply